Bladder cancer occurs when cancer cells form in the bladder, a hollow organ in the lower abdomen that stores urine. Most bladder cancers begin in the urothelium, the inner lining of the bladder, and are called urothelial carcinoma (previously known as transitional cell carcinoma). While bladder cancer most often affects the bladder lining, it can grow into deeper layers of the bladder wall over time.

Bladder cancer is commonly grouped into two main categories based on the depth of invasion:

• Non-muscle invasive bladder cancer (NMIBC):Limited to the inner lining of the bladder or the tissue just beneath it, without invasion of the bladder muscle
• Muscle-invasive bladder cancer (MIBC): Extends into the muscle layer of the bladder wall and may spread to nearby tissues or lymph nodes

This distinction directly guides treatment decisions and follow-up planning. Bladder cancer is more common in older adults and in individuals with certain risk factors, making early detection critical for improving outcomes.

At OncoClinic, we focus on accurate diagnosis and staging, clear explanations, and a personalized plan aligned to your cancer type and overall health.

Signs and symptoms

• Blood in the urine (hematuria)
• Painful urination or burning sensation during urination
• Frequent urination, especially at night
• Urgency to urinate, even when the bladder is not full
• Pelvic pain or lower back pain
• Fatigue or unexplained weight loss
• Other symptoms may include painful urination, swelling in the legs or ankles due to fluid retention, and blood in the urine

These symptoms can also be caused by other conditions such as urinary tract infections or kidney stones. If any of these symptoms persist, consult a healthcare provider for a thorough evaluation.

Risk factors

• Age: The risk of bladder cancer increases with age and is most commonly diagnosed in people over 55 years old
• Gender: Bladder cancer is more common in men than in women, although women are often diagnosed at more advanced stages
• Family history and genetics: A family history of bladder cancer may slightly increase risk, although most cases are not inherited. Rare genetic conditions can also play a role
• Smoking: Smoking is the leading risk factor for bladder cancer and is responsible for about 50% of cases. Harmful chemicals from tobacco are absorbed into the bloodstream and later filtered by the kidneys, where they damage the lining of the bladder
• Exposure to chemicals: Long-term exposure to certain industrial chemicals, especially aromatic amines used in the dye, rubber, leather, textile, and paint industries, is a well-established risk factor
• Previous cancer treatments: Certain cancer treatments increase bladder cancer risk. These include cyclophosphamide chemotherapy and radiation therapy to the pelvis
• Chronic bladder irritation: Long-term bladder irritation can increase risk. This includes conditions such as long-term use of urinary catheters and, in rare cases, chronic inflammation caused by bladder stones or parasitic infections
• Race and ethnicity: Bladder cancer is more common in white individuals compared to other racial or ethnic groups, though the reasons are not fully understood

Stopping smoking and reducing exposure to harmful chemicals are the most effective ways to lower bladder cancer risk. Understanding risk factors can help with awareness, early evaluation of symptoms, and prevention strategies.

Screening

Screening refers to testing people without symptoms. At this time, there is no routine screening program recommended for bladder cancer in the general population.

Diagnosis

Bladder cancer is usually diagnosed after a person develops symptoms, most commonly blood in the urine, which may be painless. Because symptoms are not part of screening, their presence leads to diagnostic evaluation.

Diagnostic process includes

• Urine tests: Urinalysis and urine cytology may be used to detect blood or abnormal cells in the urine. These tests can raise suspicion, but do not confirm cancer on their own
• Cystoscopy: This is a key diagnostic procedure. A thin camera is inserted through the urethra to allow the doctor to view the bladder directly and identify abnormal areas
• Transurethral resection of bladder tumor (TURBT): If a tumor is seen, it is removed through the urethra during a procedure called TURBT. This is essential both to confirm the diagnosis and to determine how deeply the cancer has grown
• Pathology (tumor analysis): The tissue removed is examined under a microscope by a pathologist.

This analysis determines:

• Whether cancer is present
• The type of cancer (most commonly urothelial carcinoma)
• Whether the cancer is non-muscle invasive (limited to the bladder lining or tissue just beneath it) or muscle-invasive (has grown into the bladder muscle)

Distinguishing between non-muscle invasive and muscle-invasive bladder cancer is critical, as it strongly influences treatment decisions.

Staging

After bladder cancer is diagnosed, additional tests are done to determine the stage of the disease. Staging describes how deeply the cancer has grown into the bladder wall and whether it has spread to lymph nodes or other parts of the body. This information is essential for choosing the most appropriate treatment and understanding what to expect.

Staging is based on the results of pathology from the bladder tumor and imaging exams, which may include:

• CT scans: Used to evaluate the bladder, nearby organs, lymph nodes, and possible spread to the abdomen, pelvis, and chest
• MRI: May be used in selected cases to provide more detailed images of the bladder and surrounding tissues
• PET/CT scan: Used in specific situations to look for cancer spread to lymph nodes or distant organs 

Bladder cancer staging

• Stage I: Cancer limited to the bladder lining: Cancer has grown into the tissue just beneath the bladder lining but has not invaded the bladder muscle. This stage is considered non-muscle invasive bladder cancer
• Stage II: Cancer spread to the bladder muscle: Cancer has grown into the muscle layer of the bladder wall but has not spread outside the bladder. This is classified as muscle-invasive bladder cancer
• Stage III: Cancer spread outside the bladder: Cancer has grown through the bladder wall into nearby tissues, such as the fat surrounding the bladder, and may involve nearby organs or lymph nodes in the pelvis
• Stage IV: Cancer spread to distant organs: Cancer has spread to distant lymph nodes or other parts of the body, such as the lungs, liver, or bones

In general, earlier stages are easier to treat and often have better outcomes, while more advanced stages may require more intensive treatment. Staging plays a key role in guiding treatment decisions and planning ongoing care.

Treatment and procedures

At OncoClinic, we provide comprehensive care for people with bladder cancer, focusing on a personalized and effective treatment approach. Our multidisciplinary team works together to develop individualized treatment plans based on the type and stage of the cancer, as well as each patient’s overall health and preferences. Our services include:

Personalized treatment plans: Treatment strategies are tailored to each patient based on whether the cancer is non-muscle invasive (NMIBC) or muscle-invasive (MIBC), the stage of disease, and individual health needs.

Surgery: Surgery is an important treatment option for many patients with bladder cancer, particularly those with muscle-invasive disease or high-risk tumors. When surgery is recommended, it is performed at one of our partner hospitals, with treatment planning, coordination, and follow-up care managed by the OncoClinic team.

Intravesical therapy: For non-muscle invasive bladder cancer, treatment may include intravesical therapy, in which chemotherapy or immunotherapy (such as BCG therapy) is delivered directly into the bladder to reduce the risk of recurrence and progression.

Chemotherapy: Systemic chemotherapy may be used before surgery, after surgery, or as the main treatment in more advanced cases. Chemotherapy works throughout the body to target cancer cells and reduce the risk of spread.

Radiation therapy: Radiation therapy uses high-energy radiation to destroy cancer cells. It may be used in combination with chemotherapy for selected patients, especially when surgery is not an option or as part of bladder-preserving treatment approaches.

Targeted therapy and immunotherapy: For advanced bladder cancer, targeted therapies and immunotherapies may be used to help the immune system recognize and attack cancer cells or to block specific pathways that help cancer grow.

Multidisciplinary care: Care is provided by a coordinated team that includes urologists, medical oncologists, radiation oncologists, nurses, and psychosocial support professionals, all working together to ensure comprehensive and well-coordinated care.

Supportive care: Supportive services such as nutritional counseling, psychological support, pain management, and rehabilitation are offered to help patients manage side effects and maintain quality of life throughout treatment.

References

Bladder cancer overview
American Cancer Society, 2026

Bladder cancer risk factors
American Cancer Society, 2026

Signs and symptoms of bladder cancer
American Cancer Society, 2026

Tests for bladder cancer (diagnosis)
American Cancer Society, 2026

Bladder cancer stages
American Cancer Society, 2026

Bladder cancer – patient version
National Cancer Institute (NCI), 2026

Bladder cancer treatment (PDQ®) – patient version
National Cancer Institute (NCI), 2026

NCCN clinical practice guidelines in oncology: bladder cancer
National Comprehensive Cancer Network (NCCN), 2026

EAU guidelines on non–muscle-invasive bladder cancer
Babjuk M et al. – European Urology, 2022

EAU guidelines on muscle-invasive and metastatic bladder cancer
Witjes JA et al. – European Urology, 2021

Diagnosis and treatment of non–muscle invasive bladder cancer
Chang SS et al. – AUA Guideline, 2016

Bladder cancer: ESMO clinical practice guidelines
Powles T et al. – Annals of Oncology, 2022

Bladder cancer statistics
Surveillance, Epidemiology, and End Results (SEER) Program, 2026

Bladder cancer
Sanli O et al. – Nature Reviews Disease Primers, 2017

Radical cystectomy in the treatment of invasive bladder cancer
Stein JP et al. – Journal of Clinical Oncology, 2001